A study to confirm the efficacy and safety of different dupilumab dose regimens in adults with atopic dermatitis (AD)

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003384-38

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study is to assess the ability of different dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with dupilumab monotherapy compared to placebo.


Critère d'inclusion

  • Atopic dermatitis